Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

Prior osteoporosis therapies may affect the skeletal response to denosumab. We compared the effect of denosumab (60  mg every 6 months for 12 months) on bone mineral density and bone metabolism parameters in postmenopausal women with low bone mass who were either treatment-naïve (n = 30), or previously treated either with zoledronic acid (n = 30), or teriparatide (n = 22).

Source: Bone - October 4, 2018 Category: Orthopaedics Authors: Elena Tsourdi, Polyzois Makras, Tilman D. Rachner, Stergios Polyzos, Martina Rauner, Stylianos Mandanas, Lorenz C. Hofbauer, Athanasios D. Anastasilakis Tags: Full Length Article Source Type: research